FLUORESCEIN SERB fluorescein sodium 500mg/5mL injection solution ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

fluorescein serb fluorescein sodium 500mg/5ml injection solution ampoule

clinect pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - fluorescein angiography of the fundus and of the iris vasculature. this medicinal product is for diagnostic use only.

PROVEBLUE methylene blue 50 mg/10 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

proveblue methylene blue 50 mg/10 ml injection ampoule

clinect pty ltd - methylene blue, quantity: 50 mg - injection - excipient ingredients: water for injections - proveblue is indicated: for the treatment of drug-induced methaemoglobinaemia. for the treatment of idiopathic methaemoglobinaemia (in which structural abnormality of haemoglobulin is not present). as a bacterial stain. as a dye in diagnostic procedures such as fistula detection. for the delineation of certain body tissues during surgery.

ZARONTIN ethosuximide 250mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

zarontin ethosuximide 250mg capsule bottle

clinect pty ltd - ethosuximide, quantity: 250 mg - capsule, soft - excipient ingredients: macrogol 400; gelatin; glycerol; quinoline yellow; erythrosine; sorbitol; 1,4-sorbitan; mannitol; titanium dioxide; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; purified water; strong ammonia solution; polyvinyl acetate phthalate - zarontin is indicated for the control of petit mal epilepsy.

ZARONTIN SYRUP ethosuximide 250mg/5mL oral liquid bottle Australia - English - Department of Health (Therapeutic Goods Administration)

zarontin syrup ethosuximide 250mg/5ml oral liquid bottle

clinect pty ltd - ethosuximide, quantity: 50 mg/ml - oral liquid, solution - excipient ingredients: citric acid monohydrate; saccharin sodium; sucrose; glycerol; sodium citrate dihydrate; sodium benzoate; purified water; flavour - zarontin is indicated for the control of petit mal epilepsy.

MONODUR isosorbide mononitrate 120 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

monodur isosorbide mononitrate 120 mg modified release tablet blister pack

clinect pty ltd - isosorbide mononitrate, quantity: 120 mg - tablet, modified release - excipient ingredients: hyprolose; hypromellose; magnesium stearate; titanium dioxide; colloidal anhydrous silica; synthetic paraffin; aluminium sodium silicate; macrogol 6000 - indications as at 08 may 2001 : monodur durules are indicated for prophylactic treatment of angina pectoris. monodur durules are not recommended for the management of acute attacks of angina pectoris (see precautions).

IMDUR isosorbide mononitrate 120 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

imdur isosorbide mononitrate 120 mg modified release tablet blister pack

clinect pty ltd - isosorbide mononitrate, quantity: 120 mg - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; synthetic paraffin; hyprolose; magnesium stearate; titanium dioxide; macrogol 6000; aluminium sodium silicate - indications as at 08 may 2001 : imdur durules are indicated for prophylactic treatment of angina pectoris. imdur durules are not recommended for the management of acute attacks of angina pectoris (see precautions).

MONODUR isosorbide mononitrate 60 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

monodur isosorbide mononitrate 60 mg modified release tablet blister pack

clinect pty ltd - isosorbide mononitrate, quantity: 60 mg - tablet, modified release - excipient ingredients: titanium dioxide; macrogol 6000; magnesium stearate; colloidal anhydrous silica; aluminium sodium silicate; hypromellose; iron oxide yellow; synthetic paraffin; hyprolose - indications as at 08 may 2001: monodur is indicated for prophylactic treatment of angina pectoris. monodur is not recommended for the management of acute attacks of angina pectoris (see precautions).

IMDUR isosorbide mononitrate 60 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

imdur isosorbide mononitrate 60 mg modified release tablet blister pack

clinect pty ltd - isosorbide mononitrate, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; titanium dioxide; iron oxide yellow; colloidal anhydrous silica; hypromellose; hyprolose; aluminium sodium silicate; macrogol 6000; synthetic paraffin - indications as at 08 may 2001: imdur is indicated for prophylactic treatment of angina pectoris. imdur is not recommended for the management of acute attacks of angina pectoris (see precautions).

METARAMINOL TORBAY metaraminol (as tartrate) 5 mg/10 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

metaraminol torbay metaraminol (as tartrate) 5 mg/10 ml injection ampoule

clinect pty ltd - metaraminol tartrate, quantity: 9.5 mg (equivalent: metaraminol, qty 5 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium metabisulfite - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. ,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

METARAMINOL TORBAY metaraminol (as tartrate)10 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

metaraminol torbay metaraminol (as tartrate)10 mg/1 ml injection ampoule

clinect pty ltd - metaraminol tartrate, quantity: 19 mg (equivalent: metaraminol, qty 10 mg) - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. ,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.